Impressive Response to Tandem Treatment With [90Y]DOTATOC and [177Lu]DOTATOC in Grade 3 Pancreatic Neuroendocrine Carcinoma.
Clin Nucl Med
; 43(7): 506-508, 2018 Jul.
Article
in En
| MEDLINE
| ID: mdl-29742602
Peptide receptor radionuclide therapy is an effective, well-tolerated, treatment for well-differentiated neuroendocrine tumors, resulting in a significant survival benefit and improvement of quality of life. Very few data are available on peptide receptor radionuclide therapy effectiveness in grade 3 neuroendocrine carcinomas with high somatostatin receptor expression. We report the case of a 70-year-old woman with metastatic pancreatic grade 3 neuroendocrine carcinoma who underwent 6 cycles of tandem treatment with investigational radiopharmaceuticals Y-DOTATOC and Lu-DOTATOC achieving an impressive response.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pancreatic Neoplasms
/
Octreotide
/
Carcinoma, Neuroendocrine
/
Radiopharmaceuticals
Aspects:
Patient_preference
Limits:
Aged
/
Female
/
Humans
Language:
En
Journal:
Clin Nucl Med
Year:
2018
Document type:
Article
Country of publication: